Lytix Biopharma AS - Mandatory Notification of Trade – Redelivery of Lent Shares to Closely Associated Party of a Primary Insider

Oslo, Norway, 27 December 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 17 December 2024, regarding the successful completion of a private placement (the "Private Placement") of new shares raising NOK 100 million in gross proceeds, and a retail offering (the "PrimaryBid Offering") of new shares raising NOK 11.3 million in gross proceeds via the PrimaryBid platform. As part of the settlement arrangements for the Private Placement and the PrimaryBid Offering, the Company had entered into a share lending agreement (the "Share Lending Agreement") with certain existing shareholders, including Saturn Invest AS ("Saturn Invest"), and the joint bookrunners of the Private Placement, Carnegie AS and DNB Markets, a part of DNB Bank ASA (the "Managers"). The share loan has today, on 27 December 2024, been settled with new shares in the Company resolved issued by the board of directors. Pursuant to the Share Lending Agreement and for the purposes stated above, the close associate of a primary insider, Saturn Invest, has received the redelivery of the previously lent out 1,318,913 shares to Carnegie AS (on behalf of the Managers). Please see the attached form for more information. Disclosure regulation: This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. For more information, please contact: Gjest Breistein, CFO +47 952 60 512 gjest.breistein@lytixbiopharma.com Lytix in brief: Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.